CureDuchenne is pleased to see our biotech partner Capricor Therapeutics progress with their HOPE-Duchenne clinical trial. Capricor announced today the treatment of the first patient with Duchenne muscular dystrophy-related […]
The Duchenne community continues its fight to get an approved treatment for Duchenne. The FDA released Briefing Document on eteplirsen, the drug for Duchenne muscular dystrophy submitted for approval […]
We wanted to share the following information from BioMarin in regards to yesterday’s news on the FDA decision on Kyndrisa (drisapersen). Dear Patient Group Representative, As you […]
Did you know that heart failure is very common and often fatal in patients with Duchenne muscular dystrophy? The Halt cardiOmyopathy ProgrEssion in Duchenne (HOPE-Duchenne) is a clinical trial […]
There has been a lot of recent Duchenne research news lately. As a community, we are glad to see a variety of research programs moving forward with positive results. […]
Following the long awaited news of Sarepta’s phase IIB results for eteplirsen and continued Phase III progress of GSK/Prosensa’s drisapersen, as well as the recent developments with PTC Therapeutics and […]